NOT KNOWN DETAILS ABOUT SEVITERONEL

Much like TNBC, the position of AR from the management of estrogen receptor-positive (ER+) breast cancer is a region of active exploration. AR is expressed in as many as 90% of ER+ tumors and preclinical information indicates that AR expression is linked to resistance to each tamoxifen and aromatase inhibitors in ER+ mobile strains [fourteen–16].